Benzinga | Apr 1, 2021 07:41AM EDT

Medivolve To Offer AditxtScore Through Its Mobile Testing Centers

Medivolve Inc. ("Medivolve") ((NEO:MEDV, OTC:COPRF, FRA:4NC)) today announced that its wholly owned subsidiary, Collection Sites, LLC will offer AditxtScore(tm) for COVID-19 through its mobile testing centres. Aditx Therapeutics (NASDAQ:ADTX), is a biotech innovation company focused on improving the health of the immune system.

Collection Sites, LLC provides testing programs to various organizations and customers in different industries, including entertainment and education. As an AditxtScore(tm) Channel Partner, Collection Sites, LLC will now offer its customers AditxtScore(tm) for COVID-19 as an immune monitoring service. Collection Sites, LLC can implement the test with current staff and no additional investment. Specimens collected by Collection Sites will be sent to and processed at Aditxt's CLIA-certified AditxtScore(tm) Centre.

"We welcome Collection Sites as an AditxtScore Channel Partner and we look forward to working with their team to expand the availability of AditxtScore for COVID-19 through their mobile testing centres," said Amro Albanna, co-Founder and CEO of Aditxt.

"As the rollout of COVID-19 vaccines progress across the United States, people are going to want to monitor their immunity levels regularly," added Medivolve CEO, Doug Sommerville. "This will be one of the many ongoing services offered through our future telehealth sites as immune responsiveness will be top of mind for people for the foreseeable future. We are excited to be able to bring this testing modality to our customers and believe it will be a significant revenue contributor now and in the future."